Generic drug maker Actavis Inc (NYSE:ACT) is reported to have spurned a $15 billion cash and stock acquisition offer from Mylan Inc. (NASDAQ:MYL). According to Bloomberg, Actavis Inc (NYSE:ACT) would decide instead to pursue talks to …
Coury. Be the first to know - Join our Facebook page. Teva offered to buy all outstanding Mylan shares for $82, some 48 percent above its March 10 price, in a halfcash, half-stock deal that it said would lead to $2b. in cost savings. Scooping …
Cecil-based generic drug maker Mylan Inc. yesterday reported a $1.38 billion loss for the quarter ended Dec. 31 and announced a restructuring that includes shrinking operations, selling the rights to its hypertension drug and the …
RadioShack (NYSE: RSH) 35.5% HIGHER; is said to have reached an agreement with a consortium led by Standard General with respect to a $590 million financing agreement. Durata Therapeutics (NASDAQ: DRTX) 10% HIGHER; …
In the same year, former Mylan CEO and chairman Robert Coury earned $98 million. Coury’s salary was technically only $1.6 million but he received a $20 million bonus, $50.8 million in stock awards and $22.7 million listed as "other …
Generic drug firm Mylan has offered to buy over-the-counter rival Perrigo in a cash and stock deal that would create a pharmaceutical powerhouse. The global drug firm is offering nearly $30bn (£20bn; €28bn) for Ireland-based Perrigo, …
HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange
NEW YORK (AP) — Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development. If Teva manages to acquire Mylan under the offer announced Tuesday, it …
The drugmaker's shares rallied Monday following Friday's settlement with the Justice Department, resolving claims by Medicaid that Mylan overcharged the government health program for the allergy shot. That helped erase some of the …
NEW YORK — Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. …